Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

  1. Our Science
FILTER
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Effect of Bimekizumab on Patient-Reported Disease Impact in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies 

Laure Gossec, Orbai Ana-Maria, Maarten de Wit et al.  May 16, 2024
phase 4

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

The Cost-Effectiveness of a Bimekizumab Versus IL-17A Inhibitors Treatment-Pathway in Patients with Active Axial Spondyloarthritis in Scotland

Mørup Michael Frank, Taieb Vanessa, Willems Damon et al.  May 02, 2024
phase 3

RYSTIGGO® (rozanolixizumab-noli)

Generalized Myasthenia
Gravis
View

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Bril Vera, Drużdż Artur, Grosskreutz Julian et al.  May 01, 2024
phase 3

ZILBRYSQ® (zilucoplan)

Generalized Myasthenia
Gravis
View

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

James F Howard Jr, Bresch Saskia, Constantine Farmakidis et al.  April 17, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2 

Navarro-Compán Victoria, Ramiro Sofia, Deodhar Atul et al.  April 10, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials

Lebwohl Mark, Joseph F Merola, Strober Bruce et al.  April 06, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab-bkzx Journal Scan: 4 Clinical Trials

Jason Hawkes et al.  March 25, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison 

Richard B Warren, Iain B McInnes, Nash Peter et al.  March 15, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials

Gordon B. Kenneth, Langley G. Richard, Warren B. Richard et al.  March 15, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison 

Philip J Mease, Richard B Warren, Nash Peter et al.  March 06, 2024